home / stock / halo / halo news

HALO News and Press, Halozyme Therapeutics Inc. From 02/10/20

Stock Information
Company Name: Halozyme Therapeutics Inc.
Stock Symbol: HALO
Market: NASDAQ
Website: halozyme.com
Menu
HALO HALO Quote HALO Short HALO News HALO Articles HALO Message Board
Get HALO Alerts

News, Short Squeeze, Breakout and More Instantly...
HALO - Halozyme To Host Fourth Quarter And Full Year 2019 Financial Results Webcast And Conference Call

SAN DIEGO , Feb. 10, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quarter 2019 on Monday, February 24 at 4:30 p.m. ET / 1:30 p.m. PT . Dr. Helen Torley , president and chief executive officer, w...
HALO - JPMorgan likes Centene in premarket analyst action

ICAD (NASDAQ: ICAD ) initiated with Market Perform rating and $15 (163% upside) price target at JMP Securities. More news on: iCAD, Inc., National Health Investors, Inc., Sabra Health Care REIT, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

HALO - Halozyme Provides 2020 Business Update And Financial Guidance

SAN DIEGO , Jan. 14, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today provided an update on its outlook for 2020, including financial guidance. "We have made tremendous progress repositioning the company to focus solely on driving the growth and profitability o...

HALO - UBS upgrades Madrigal Pharma in premarket analyst action

Aptose Biosciences (APS CN) initiated with Overweight rating at Piper Sandler. Shares up  2%  premarket in U.S. (NASDAQ: APTO ). More news on: Aptose Biosciences Inc., BioDelivery Sciences International, Inc., BiomX Inc., Healthcare stocks news, Stocks on the move, , Read mor...
HALO - More healthcare new coverage ahead of JPM20

Agilent (NYSE: A ) initiated with Overweight rating and $100 (18% upside) price target at Wells Fargo. More news on: Agilent Technologies, Inc., Avantor, Inc., Axonics Modulation Technologies, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

HALO - Halozyme Therapeutics To Present At The 38th Annual J.P. Morgan Healthcare Conference

SAN DIEGO , Jan. 3, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16 at 8:30 a.m. PT / 11:30 a.m. ET . Dr. Helen Torley , president and chief executive o...

HALO - Data From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's ENHANZE® Drug Delivery Technology To Be Presented At San Antonio Breast Cancer Symposium

SAN DIEGO , Dec. 12, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that new data from the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, will be presented today at the 2019 San Antonio Breast Cancer Symposium (SABCS)....
HALO - Halozyme prices convertible debt offering; shares ahead 2% premarket

Halozyme (NASDAQ: HALO ) prices its private offering of $400M of 1.25% Convertible Senior Notes due 2024 at par. The initial conversion rate is 41.9208 (~$23.85/common share). More news on: Halozyme Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

HALO - Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $400 Million of Convertible Senior Notes due 2024

SAN DIEGO , Nov. 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (the "Company"), a biotechnology company focused on novel biological and drug delivery approaches, today announced the pricing of $400.0 million aggregate principal amount of its convertible senior note...

HALO - Halozyme Therapeutics Inc (HALO) Q3 2019 Earnings Call Transcript

Image source: The Motley Fool. Halozyme Therapeutics Inc   (NASDAQ: HALO) Q3 2019 Earnings Call Nov 12, 2019 , 4:30 p.m. ET Operator Continue reading

Previous 10 Next 10